Cytokine Gene Polymorphisms Are Not Associated With Bronchiolitis Obliterans Syndrome or Survival After Lung Transplant

“…(25) demonstrated that the macrolide antibiotic clarithromycin can significantly prevent tracheal fibro‐obliteration by down‐modulating TNF‐α and γ‐IFN production. Increased levels of IL‐8 and other pro‐inflammatory mediators in BAL, as well as neutrophilia, have been observed in some LTRs with established or future BOS, and some of these features have been shown to pre‐date BOS onset (8–13, 30, 31). Such an airway inflammatory response has been reported by some authors to represent a prerequisite for the response to AZI therapy in BOS (18, 19, 23).…”

Section: Discussionmentioning

confidence: 99%

Clinical and immunological evaluation of 12‐month azithromycin therapy in chronic lung allograft rejection

Meloni¹,

Solari²,

Morosini³

et al. 2011

Clinical Transplantation

View full text Add to dashboard Cite

show abstract

“…53 Genetic polymorphisms leading to increased production of TGF-b have been implicated in the increased mortality due to BOS seen in IPF, 52 though this has not been a consistent finding. 54 The process of epithelial to mesenchymal transition (EMT) also appears to play a role in the development of BOS. EMT is a process by which fully differentiated epithelial cells transition to a mesenchymal phenotype and is a potential source of activated fibroblasts in the airways of those with BOS.…”

Section: Bronchiolitis Obliterans Syndrome and Idiopathic Pulmonary Fmentioning

confidence: 99%

Interstitial Lung Disease and Lung Transplantation

O’Beirne

Counihan

Keane

2010

Semin Respir Crit Care Med

View full text Add to dashboard Cite

Idiopathic pulmonary fibrosis (IPF) is the most common of the idiopathic interstitial pneumonias and carries the worst prognosis. Currently the best treatment option is lung transplantation. Historically patients with IPF had poor outcomes following referral for lung transplant due to high waiting-list mortality. The introduction of the lung allocation score in the United States in 2005 has reduced 1 year waiting-list mortality from 21% to 11% and also led to IPF becoming the most common diagnosis for lung transplantation. Although prioritizing all patients with IPF on the waiting list has led to a dramatic decline in waiting-list mortality, further improvements may be made by prioritizing which patients with IPF should be transplanted, with an emphasis on 6-minute walk testing, biomarkers, and the presence of pulmonary hypertension rather than traditional pulmonary function tests. The choice of surgical procedure and the prediction and management of posttransplant complications may also influence long-term outcomes.

show abstract

Cytokine Gene Polymorphisms Are Not Associated With Bronchiolitis Obliterans Syndrome or Survival After Lung Transplant

Cited by 20 publications

References 23 publications

Analysis of cytokine pattern in exhaled breath condensate of lung transplant recipients with bronchiolitis obliterans syndrome

Analysis of cytokine pattern in exhaled breath condensate of lung transplant recipients with bronchiolitis obliterans syndrome

Clinical and immunological evaluation of 12‐month azithromycin therapy in chronic lung allograft rejection

Interstitial Lung Disease and Lung Transplantation

Contact Info

Product

Resources

About